Multi-Modality Treatment of Resectable Oesophageal Adenocarcinoma Using Peri-Operative Chemotherapy With Additional Pre-Operative Combined Radiotherapy and Cetuximab.

Trial Profile

Multi-Modality Treatment of Resectable Oesophageal Adenocarcinoma Using Peri-Operative Chemotherapy With Additional Pre-Operative Combined Radiotherapy and Cetuximab.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Jan 2014

At a glance

  • Drugs Cetuximab (Primary) ; Cisplatin; Epirubicin; Fluorouracil
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Acronyms TRACC
  • Most Recent Events

    • 25 Oct 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 25 Oct 2010 Planned end date changed from 1 Sep 2011 to 1 Aug 2010 as reported by ClinicalTrials.gov.
    • 12 Mar 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top